Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Echogenic Swirling Seen on Ultrasound and Outcome of Pleurodesis in Malignant Pleural Effusion.

Hassan M, Asciak R, Mercer RM, McCracken DJ, Tsikrika S, Shaarawy H, Elganady A, Wrightson JM, Rahman NM.

Arch Bronconeumol. 2019 Jun 13. pii: S0300-2896(19)30262-5. doi: 10.1016/j.arbres.2019.05.010. [Epub ahead of print] English, Spanish. No abstract available.

2.

Computed tomography abnormalities antedating mesothelioma diagnosis: a perspective on the natural history.

Hassan M, Tsikrika S, Asciak R, Mercer RM, El-Ganady A, Rahman NM.

Eur Respir J. 2019 Feb 28;53(2). pii: 1800935. doi: 10.1183/13993003.00935-2018. Print 2019 Feb. No abstract available.

PMID:
30442717
3.

Chest Wall Seroma Following Surgery for Malignant Pleural Effusion.

Hassan M, Tsikrika S, Rahman NM.

Arch Bronconeumol. 2019 May;55(5):266. doi: 10.1016/j.arbres.2018.09.016. Epub 2018 Nov 5. English, Spanish. No abstract available.

4.

Chest Drain Fall-Out Rate According to Suturing Practices: A Retrospective Direct Comparison.

Asciak R, Addala D, Karimjee J, Rana MS, Tsikrika S, Hassan MF, Mercer RM, Hallifax RJ, Wrightson JM, Psallidas I, Benamore R, Rahman NM.

Respiration. 2018;96(1):48-51. doi: 10.1159/000489230. Epub 2018 Jun 14.

5.

The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis.

Tsikrika S, Dimakou K, Papaioannou AI, Hillas G, Thanos L, Kostikas K, Loukides S, Papiris S, Koulouris N, Bakakos P.

Cytokine. 2017 Nov;99:281-286. doi: 10.1016/j.cyto.2017.08.005. Epub 2017 Aug 31.

PMID:
28863927
6.

Patterns of drug resistance among patients with tuberculous pleural effusion in Greece.

Anastasakos V, Skouras V, Moschos C, Tsikrika S, Karabela S, Marinou I, Vogiatzakis E, Konstantinou K, Papavasiliou A, Kalomenidis I.

Int J Tuberc Lung Dis. 2017 Mar 1;21(3):309-313. doi: 10.5588/ijtld.16.0155.

PMID:
28225341
7.

Distribution of nontuberculous mycobacteria in treated patients with pulmonary disease in Greece - relation to microbiological data.

Manika K, Tsikrika S, Tsaroucha E, Karabela S, Karachaliou I, Bosmi I, Kioumis I, Papavasileiou A.

Future Microbiol. 2015;10(8):1301-6. doi: 10.2217/FMB.15.50. Epub 2015 Jul 30.

PMID:
26226382
8.

Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk?

Papaioannou AI, Bartziokas K, Loukides S, Tsikrika S, Karakontaki F, Haniotou A, Papiris S, Stolz D, Kostikas K.

Eur Respir J. 2015 Sep;46(3):846-9. doi: 10.1183/09031936.00237014. Epub 2015 Apr 16. No abstract available.

9.

Prediction of hospitalization stay in COPD exacerbations: the AECOPD-F score.

Diamantea F, Kostikas K, Bartziokas K, Karakontaki F, Tsikrika S, Pouriki S, Polychronopoulos V, Karagiannidis N, Haniotou A, Papaioannou AI.

Respir Care. 2014 Nov;59(11):1679-86. doi: 10.4187/respcare.03171. Epub 2014 Jun 24.

10.

Collateral damage: depressive symptoms in the partners of COPD patients.

Papaioannou AI, Tsikrika S, Bartziokas K, Karakontaki F, Kastanakis E, Diamantea F, Haniotou A, Papiris S, Polychronopoulos V, Loukides S, Kostikas K.

Lung. 2014 Aug;192(4):519-24. doi: 10.1007/s00408-014-9595-4. Epub 2014 May 11.

PMID:
24816968
11.

Fatal case of extensively drug-resistant Mycobacterium tuberculosis Beijing genotype infection in an injecting drug user, Athens, Greece, 2012.

Leuow K, Papaventsis D, Kourkoundi S, Ioannidis P, Karabela S, Tsikrika S, Marinou I, Papavasileiou A, Stone M, Drobniewski F, Paparisos V, Vogiatzakis E.

Euro Surveill. 2013 Mar 21;18(12). pii: 20430.

12.

The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations.

Papaioannou AI, Bartziokas K, Tsikrika S, Karakontaki F, Kastanakis E, Banya W, Haniotou A, Papiris S, Loukides S, Polychronopoulos V, Kostikas K.

Eur Respir J. 2013 Apr;41(4):815-23. doi: 10.1183/09031936.00013112. Epub 2012 Aug 9.

13.

Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.

Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, Hadziyannis E.

Clin Vaccine Immunol. 2011 Dec;18(12):2102-8. doi: 10.1128/CVI.05299-11. Epub 2011 Oct 12.

Supplemental Content

Loading ...
Support Center